Paul Shekelle, MD
Shekelle P. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years. Ann Intern Med. 2016;164:JC2. doi: https://doi.org/10.7326/ACPJC-2016-164-2-002
Download citation file:
Published: Ann Intern Med. 2016;164(2):JC2.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use